Varenicline and bupropion sustained-release combination therapy for smoking cessation
- 25 February 2009
- journal article
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
- Vol. 11 (3) , 234-239
- https://doi.org/10.1093/ntr/ntn031
Abstract
Introduction: Varenicline and bupropion sustained release (SR) are both safe and effective for the treatment of tobacco dependence and have different mechanisms of action. Combination pharmacotherapy with these agents may increase long-term smoking abstinence rates above what is observed with single-agent therapy.Keywords
This publication has 23 references indexed in Scilit:
- Effects of abstinence from tobacco: Valid symptoms and time courseNicotine & Tobacco Research, 2007
- METABOLISM AND DISPOSITION OF VARENICLINE, A SELECTIVE α4β2 ACETYLCHOLINE RECEPTOR PARTIAL AGONIST, IN VIVO AND IN VITRODrug Metabolism and Disposition, 2006
- Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking CessationJournal of Medicinal Chemistry, 2005
- Nicotine Activation of α4* Receptors: Sufficient for Reward, Tolerance, and SensitizationScience, 2004
- Measures of abstinence in clinical trials: issues and recommendationsNicotine & Tobacco Research, 2003
- Biochemical verification of tobacco use and cessationNicotine & Tobacco Research, 2002
- Combined Use of Nicotine Patch and Gum in Smoking Cessation: A Placebo-Controlled Clinical TrialPreventive Medicine, 1995
- The Fagerström Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance QuestionnaireBritish Journal of Addiction, 1991
- The Contemplation Ladder: Validation of a measure of readiness to consider smoking cessation.Health Psychology, 1991
- The CES-D ScaleApplied Psychological Measurement, 1977